ArticleMaterials today. Bio2025
Sequential drug-release microsphere system for scarless wound healing.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mechano-immunomodulatory biomaterials: From immune mechanosensing to translational design.Bioactive materials · 2026Review
- Advancements in Functional Polymeric Scaffolds for Scar-Free Skin Regeneration.Polymer science & technology (Washington, D.C.) · 2026Review
- Collagen-Based Microspheres for Biomedical Applications in Drug Delivery and Tissue Engineering.Biomimetics (Basel, Switzerland) · 2026Review
- Approaching Scarless Wound Healing: From Passive Anti-Fibrotic to Proactive and Programmable Pro-Regenerative Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dynamic imbalance in skin wound healing is a key factor of hypertrophic scar (HS) formation. Traditional treatments often target only a certain stage of the wound healing process and fail to comprehensively address the dynamic imbalance, thus making it difficult to achieve scarless wound healing. This study developed a chronologically adaptive methacrylylated gelatin (GelMA)-based microsphere delivery system (G/E/T) that achieves comprehensive intervention in wound healing process through precisely orchestrated sequential release of epigallocatechin gallate (EGCG) and triamcinolone acetonide (TA). In vitro studies have confirmed that the G/E/T microsphere system, utilizing this sequential release mechanism, not only alleviates oxidative stress and inflammatory responses in the early stages but also persistently inhibits the excessive proliferation and migration of fibroblasts in the later phases, demonstrating stage-specific therapeutic precision. Moreover, validated through mouse full-thickness wound model and rabbit ear HS model, the system exhibited remarkable scarless healing outcomes. The "sequential release and dual-agent synergy" design paradigm provides an innovative strategy for scarless wound healing while establishing a foundational framework for developing sequential multidrug delivery systems targeting complex pathological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.